

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
11 March 2004 (11.03.2004)

PCT

(10) International Publication Number
WO 2004/021009 A2

(51) International Patent Classification⁷: G01N 33/574

(72) Inventors; and

(21) International Application Number:
PCT/CA2003/001311

(75) Inventors/Applicants (for US only): YOUSEF, George [EG/CA]; 300 Prince Phillip Drive, St. John's, Newfoundland & Labrador A1B 3V6 (CA). DIAMANDIS, Eleftherios, P. [CA/CA]; 44 Gerrard Street West, Suite 1504, Toronto, Ontario M5G 2K2 (CA).

(22) International Filing Date: 28 August 2003 (28.08.2003)

(74) Agent: KURDYDYK, Linda: McCarthy Tetrault, Suite 4700, P.O. Box 48, 66 Wellington Street West, Toronto Dominion Bank Tower, Toronto, Ontario M5K 1E6 (CA).

(25) Filing Language: English

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(26) Publication Language: English

(30) Priority Data:
60/407,332 28 August 2002 (28.08.2002) US

(71) Applicant (for all designated States except US): MOUNT SINAI HOSPITAL [CA/CA]; 600 University Avenue, Toronto, Ontario M5G 1X5 (CA).

[Continued on next page]

(54) Title: METHODS FOR DETECTING ENDOCRINE CANCER



(57) Abstract: Kallikrein 13 constitutes a novel biomarker for diagnosis, treatment and monitoring of endocrine cancer. A method is provided for diagnosing and monitoring endocrine cancer or a predisposition to endocrine cancer, in a subject comprising detecting hK13 in a sample from the subject. Imaging methods, screening methods for test agents for inhibiting breast or ovarian cancer, and therapeutic applications based on kallikrein 13 are also described.

WO 2004/021009 A2